免疫检查点抑制剂的发展概况(4)
[5] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma [J]. N Engl J Med, 2015, 372(26): 2521-2532.[6] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J]. Lancet ......
您现在查看是摘要页,全文长 2910 字符。